Spontaneous correction or reversion of an inherited variant to a normal genetic status in a stem cell that then repopulates the bone marrowwith unaffected cells.
« Back to Glossary IndexNews
Related News
Institution: Laboratorio de Citogenetica, Instituto Nacional de Pediatría, Mexico City, México Area of expertise: Medical genetics, dysmorphology. My work: I am a medical geneticist from Mexico City, introduced to the field of Fanconi anemia (FA) by my mentor, Dr. Sara Frias, whom...
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
That's why we're thrilled to announce the launch of the Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity in partnership with the American Association for Cancer Research (AACR).